Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Scynexis Inc.

  • Marco Taglietti, Scynexis

SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.

  • Date:Monday, February 11
  • Time:3:30 PM - 3:45 PM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company HQ Zip:07302
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23639
  • Goal for Presentation:Investor/BD exposure
  • Company Website:https://www.scynexis.com/
  • Company HQ City:Jersey City
  • Company HQ State:New Jersey
  • Company HQ Country:United States
  • Ticker:SCYX
  • Exchange:NASDAQ
  • CEO/Top Company Official:Marco Taglietti
  • Main Therapeutic Focus:Infectious Diseases
  • Lead Product in Development:Ibrexafungerp (formerly SCY-078)
  • Development Phase of Primary Product:Phase III
Speakers
Marco Taglietti
Scynexis
Back